

### Publishable Summary

This quarterly report provides an overview of the project progress within the AMYPAD Prognostic and Natural History Study (PNHS) (WP4), with a focus on the period from October to December 2020.

In Q4, the COVID-19 crisis (second wave across European countries) has resulted in a persistently slow recruitment of participants. However, both recruitment and scanning numbers slightly improved compared to Q3 2020 due to approvals of the global amendment at most sites at the end of Q4 (except for UK and Sweden), together with shorter periods of more lenient local COVID-19 measures at some sites.

In total, at the end of Q4 2020, AMYPAD PNHS had 754 participants consented of which 584 already underwent PET scanning. Moving forward, the Q1 of 2021 should see the approval of the global amendment in the remaining sites, and it is expected that all sites will resume recruitment. Finally, despite the progress in vaccination across Europe, Q1 2021 recruitment rates should still be reduced as most countries continue to implement strict regulations regarding COVID-19.

**For more information:** [info@amypad.org](mailto:info@amypad.org)

**Acknowledgement:** This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

